Skip Navigation LinksHome > Blogs > The Tox Cave
The Tox Cave
The Tox Cave will dissect interesting ED cases from the perspective of a toxicologist, focusing on applying up-to-date management of the poisoned patient. The name Tox Cave was coined by a former toxicology fellow to describe our small office space, likening it to the Bat Cave. The Tox Cave is where Drexel toxicology fellows and attendings have gathered to discuss the nuances of toxicology over the years.
Tuesday, March 31, 2015

A 42-year-old man presented with somnolence. His initial vital signs were heart rate 54 bpm, blood pressure 92/68 mm Hg, temperature 37°C, respiratory rate 6, and pulse oximetry 90% on room air. His physical examination was remarkable for depressed level of consciousness, miosis, and bradypnea. His mental status and respiratory rate temporarily improved with the administration of 0.04 mg naloxone. He reports swallowing several “patches” in a suicide attempt.


Popular transdermal patches are listed in the table. Others include diclofenac, buprenorphine, hormone patches (estrogen, contraceptive, testosterone), methylphenidate, and rivastigmine. It is important to consider the potentially significant quantity of drug contained in transdermal patches even after being used.



The patches are designed to deliver small quantities of the drug over a long period of time into the outer layers of skin, and it is absorbed into the deeper layers and then to the bloodstream, which circulates it throughout the body. Several types of transdermal delivery systems are available; fentanyl patches, for example, are available as a reservoir system and matrix system. (Figure 1.)


Reservoir system (left) and Matrix system (right). Derived from Duragesic and Mylan package inserts.


Swallowing, sucking, transmucosal absorption by placement of pieces in mouth, brewing it as a tea to ingest or inject, chewing whole or in pieces, extracting with a needle for injection, eluting with a solvent for injection, pyrolyzing patches for inhalation, rectal insertion, insufflation, transdermal application on abraded skin, applying heat to transdermally applied patch, and dermal application of multiple patches.


Some considerations for transdermal patch exposures include:

n Continued drug delivery from skin depots

    Blood nicotine levels remain elevated for six to 12 hours after removal of a patch.

    The apparent half-life of fentanyl delivered by transdermal patches is about 17 hours after removal of a patch from the skin.

n Supratherapeutic levels may result from skin conditions: application of external heat source (hot tubs, heating pad, etc.), abraded skin, multiple patches, or from physical patch damage resulting in uncontrolled drug release.

n Significant amount of drug remains in used patches

    Studies were conducted on 25 mcg/hour and 100 mcg/hour patches after three days of continuous use, and it was determined that there was 700 to 1220 mcg left in the 25ug/hour patches and 4460 and 8440 mcg in the 100 mcg/hour patches.


Initial management of transdermal patch ingestions includes the identification and standard treatment for the suspected drug. During the primary survey, the patient should be disrobed to allow for a complete survey for any transdermal patches, which should be removed and, subsequently, the skin should be decontaminated with copious amounts of water. GI decontamination with whole bowel irrigation should be strongly considered because these patches contain potentially lethal doses of each drug and their ingestion may lead to altered absorption of the drug.


There are no specific labs outside of the typical toxicology labs that should be ordered to help guide the treatment of these ingestions. It is worth noting that fentanyl is not detected on the standard urine drug screens. Imaging is not typically helpful because standard abdominal radiographs are not reliable in detecting patches. All patients should be admitted and monitored because the onset and duration of symptoms may be unpredictable.


The patient had recurrence of somnolence and bradypnea in the ED. He was started on a naloxone infusion and admitted to the intensive care unit. Whole bowel irrigation was administered. The following morning, the naloxone infusion was discontinued and the patient remained asymptomatic for 12 hours after the naloxone infusion was discontinued. He was medically cleared shortly after.



1. Package inserts for Catapres-TTS (clonidine), Duragesic (fentanyl), Lidoderm (lidocaine 5% patch), NicodermCQ (nicotine), Nitro-Dur (nitroglycerin), and Transderm Scōp (scopolamine).

2. Nelson L, Schwaner R. Transdermal Fentanyl: Pharmacology and Toxicology. J Med Toxicol 2009;5(4):230.

3. Prosser JM, Jones BE, Nelson L. Complications of Oral Exposure to Fentanyl Transdermal Delivery System Patches. J Med Toxicol 2010;6(4):443.

4. Montalto N, Brackett CC, Sobol T. Use of Transdermal Nicotine Systems in a Possible Suicide Attempt. J Am Board Fam Prac 1994;7(5):417.

5. Marquardt KA, Tharratt RS, Musallam NA. Fentanyl Remaining in a Transdermal System following Three Days of Continuous Use. Ann Pharmacother 1995;29(10):969.


Read more about transdermal patches in our archive.


Facebook Twitter

Monday, March 02, 2015

A 21-year-old man presented with palpitations, tremulousness, nausea, and vomiting. He reported ingesting one 14 mg nicotine patch in a suicide attempt. Initial vital signs include heart rate 132 bpm, blood pressure 140/80 mm Hg, temperature 37°C, respiratory rate 26 bpm, and pulse oximetry 100% on room air. Physical examination is remarkable for agitation, fine resting tremor, tachycardia, and pressured speech.


The lethal dose of nicotine is estimated to range from 1 mg/kg to 10 mg/kg. Reports of nicotine toxicity have occurred with the ingestion of as little as one whole cigarette or three cigarette butts in children under 6. E-cigarette consumption is on the rise, and cases of nicotine toxicity have been reported in children who have ingested the e-cigarette solution. The concentration of the nicotine refills is variable, containing 6 mg/ml (0.6%) to 100 mg/ml (10%). Assuming that 1 ml of solution is equal to 20 drops, one drop of the 10% solution would contain 5 mg of nicotine. Ingestion of as little as one drop of this concentrated solution would cause severe symptoms in children under 6.


Nicotine is well absorbed by various routes, the most rapid route being inhalation (5-60 seconds), followed by the buccal mucosa (15-30 minutes), GI tract (30-90 minutes), and dermal (4.2 hours). Nicotine has an elimination half-life of one to four hours, but the half-life may be shorter with habitual cigarette smoking and longer in dermal exposures.


The toxic effects of nicotine are caused by its stimulation of the postsynaptic nicotinic acetylcholine receptors in the autonomic nervous system. Symptoms are dose-dependent with lower doses producing stimulation of the sympathetic and parasympathetic nervous systems (tachycardia, diaphoresis, agitation) and higher doses producing stimulation of the neuromuscular endplates leading to neuromuscular blockade (seizures, weakness, paralysis, respiratory arrest).


Clinical symptoms of nicotine toxicity are divided into early and late symptoms. Early symptoms may include vomiting (the most common symptom, occurring in 50 percent of patients), salivation, diaphoresis, abdominal pain, hypertension, tachycardia, dizziness, headache, and seizures. Late symptoms may include diarrhea, hypoventilation, bradycardia, dysrhythmias, apnea, and paralysis. The duration of symptoms is typically one to two hours for mild toxicity while more severe symptoms generally resolve within 12 to 24 hours.


All contaminated clothing and nicotine patches should be removed and the skin decontaminated with soap and water. Medical staff should use standard precautions because nicotine can be transdermally absorbed. Activated charcoal adsorbs nicotine well, but it must be carefully considered because of the incidence of vomiting, seizures, and paralysis, which increase the risk for aspiration.


The use of whole bowel irrigation should be considered in patients who have ingested a nicotine patch because of the potential for significant toxicity. This is accomplished by administering 1-2 L of polyethylene glycol per hour (in adults) via a nasogastric tube until the rectal effluent is clear. No randomized control trials demonstrate a reduction in morbidity or mortality with its use, however.


Patients should be placed on a continuous cardiac monitor and pulse oximetry. Useful studies may include glucose, electrolytes, and electrocardiogram. Specific levels for nicotine and its metabolite cotinine may be available, but are not useful in acutely managing these patients.


Treatment for acute nicotine toxicity is supportive care. Patients manifesting signs of severe toxicity may need to be intubated early because of concern for paralysis and respiratory failure. Benzodiazepines should be used liberally to treat tachycardia, agitation, and seizures. Patients with protracted or intractable vomiting can be treated with antiemetics. Atropine can be used to treat bradycardia. IV fluids should be used to treat hypotension and potentially pressors for hypotension refractory to fluids.


This patient was admitted to a telemetry bed for nicotine toxicity. Whole bowel irrigation was administered, and the patient required Ativan for agitation. The following morning the patient’s vital signs and mental status normalized, and he was transferred to a psychiatric facility.


Suggest Reading

1. Mayer B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century. Arch Toxicol. 2014;88(1):5.

2. Soghian S. Nicotine. In: Nelson LS, Lewin NA, et al., eds. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill, 2011:1185.

3. Cantrell L. Nicotine poisoning. California Poison Control System. 2005;3(2):



Facebook Twitter

Monday, February 02, 2015

A 27-year-old woman with no past medical history presented to the ED by EMS after being found unresponsive at home by her partner. EMS reported that she was unresponsive with a GCS of 3, pinpoint pupils, and sonorous breath sounds. Naloxone 0.4 mg IV was administered, and the patient became responsive. The patient was delirious, agitated, and tachycardic upon arrival to the ED. She was administered lorazepam 2 mg IV without improvement. Her agitation and delirium were so severe that she was intubated, paralyzed with rocuronium, and started on a midazolam infusion.


What is the appropriate dose of IV naloxone?

No consensus exists on the appropriate starting dose of naloxone, but many toxicologists recommend a starting dose of naloxone 0.04 mg IV in opioid-dependent patients, quickly titrating up every two minutes to a maximum of 10 mg. If no effects are seen after 10 mg, the patient’s respiratory or CNS depression are unlikely to be a result of opioid toxicity. Special considerations should be taken in certain populations, including opiate-naive patients and children where larger doses of Narcan can be used initially to reverse the respiratory depression.


Adverse effects have been reported at doses as low as 0.4 mg IV, which support a starting dose of 0.04 mg. It is important to remember that most adverse effects are from acute opioid withdrawal rather than to the naloxone itself.


To administer naloxone 0.04 mg IV, dilute a naloxone preparation of 0.4 mg/1ml ampule in a 10 ml syringe of normal saline, and then administer the medication 1 ml at a time.


What is the relationship between naloxone and pulmonary edema?

Pulmonary edema and acute lung injury following naloxone administration for opioid-toxic patients has been described, but it remains controversial whether acute lung injury is from acute withdrawal precipitated by naloxone or to opioid-induced complications.


Several mechanisms relating naloxone to pulmonary complications have been proposed, such as naloxone to reverse the profound respiratory depression leading to more apparent opioid-induced pulmonary findings. Another mechanism of action for naloxone-induced pulmonary edema is the catecholamine surge. A study by Kienbaum, et al., in 1998 demonstrated a 30-fold increase in epinephrine levels after naloxone administration in opioid-dependent patients. (Anesthesiology 1998;88[5]:1154.) Interestingly, this catecholamine surge has been shown to be exacerbated by hypoventilation or hypercapnia in canines.


Other explanations for pulmonary edema that occurs in the opioid-toxic or anesthesia patients who received naloxone include inherent toxicity of opioids themselves, co-administered drugs, or other underlying disease processes.


What serious cardiovascular complications have been reported in association with the administration of naloxone?

Serious cardiovascular effects include arrhythmias such as ventricular tachycardia, myocardial infarction, cardiomyopathy, and heart failure. These complications are rarely reported, and may actually be the result of hypoxia, inherent toxicity of the opioids themselves, co-intoxication with another agent (such as cocaine), or pre-existing cardiac disease. The mechanism is thought to be from catecholamine release induced by precipitated opioid withdrawal or unmasking of sympathomimetic agents.


What are other adverse effects related to the administration of naloxone?

Many of the adverse effects related to the administration of naloxone are from acute opioid withdrawal.




Managing patients who have received naloxone for opioid intoxication.

Prior to administering naloxone, one may consider providing sufficient ventilation to potentially reduce the catecholamine surge that is believed to be exacerbated by elevated CO2, and therefore possibly decrease the incidence of the more serious adverse effects listed above.


Patients who received naloxone for opioid intoxication should be closely monitored for recurrence of respiratory depression and sedation, particularly in patients who have ingested long-acting opiates or opioids (methadone) or transdermal patches. These patients should be on continuous cardiac and pulse oximetry monitoring because the half-life of naloxone (30-80 minutes) is generally shorter than most opioids. Redevelopment of respiratory depression requires repeat administration of naloxone. Oxygen should only be administered if the patient becomes hypoxic because it may delay detecting hypoventilation as a normal pulse oximetry reading and will not reflect developing hypercapnia. Some physicians for this reason recommend continuous end-tidal CO2 monitoring in these patients because this is a more accurate indicator of a patient’s ventilatory effort.


Symptomatic support should be provided to help alleviate the uncomfortable symptoms if opioid withdrawal occurs. Clonidine, an alpha-2 adrenergic receptor agonist, has been shown to be effective in cases of autonomic instability (i.e., tachycardia, hypertension).


Disposition of a patient who received naloxone for opioid intoxication.

The disposition of a patient who has received naloxone in the ED must be carefully considered. The pharmacological effects of naloxone are shorter than most opioids used, and some patients are at risk for re-sedation or respiratory depression after the effects of naloxone have worn off. It is prudent to monitor patients for at least six hours after they have been administered naloxone for redeveloping symptoms and to consider admission of patients who have required two or more doses of naloxone.


A special consideration must be made in patients who have ingested long-acting opioids/opiates. Patients who have ingested sustained-release formulations (e.g, MS Contin), long-acting opioids (methadone), or one or more fentanyl patches require admission for 24-hour observation.


This patient required sedation and eventually intubation because of her severe delirium and agitation, but the majority of patients rarely experience adverse effects as a result of naloxone administration.


Suggested Reading:

1. Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: Walking the tightrope. Emerg Med J 2005;22(9):612.

2. Lameijer H, Azizi N, et al. Ventricular tachycardia after naloxone administration: A drug related complication? Case report and literature review. Drug Safety-Case Reports 2014;1:1.

3. Spadotto V, Zorzi A, et al. Heart failure due to ‘stress cardiomyopathy’: A severe manifestation of the opioid withdrawal syndrome. Eur Heart J Acute Cardiovasc Care 2013;2(1):84.


Facebook Twitter

Friday, January 02, 2015

A 44-year-old-man with a past medical history of alcohol abuse was brought to the emergency department by EMS. He was found sleeping on a bench and appeared intoxicated. His initial vital signs were temperature 90.9°F, heart rate 62 bpm, blood pressure 130/84 mm Hg, respiratory rate 16 bpm, and pulse oximetry 98% on room air. He is disheveled patient, and has a depressed level of consciousness, slurred speech, and the distinct odor of mint and urine. Pertinent lab findings include an ethanol level of 340 mg/dL.


The minty odor is tipoff in this case that he is inebriated from mouthwash. The ethanol concentration in mouthwashes commercially available in the United States varies widely. The highest ethanol concentration reported is 26.9%. Alcohol-free products are also available.




The risk of toxicity from the nonalcoholic ingredients is minimal in most ingestions of mouthwash:



One standard drink is equivalent to 2.2 fluid ounces of 27% alcohol/volume mouthwash:


National Institute on Alcohol Abuse and Alcoholism;


It is important to recognize the signs of ethanol intoxication in patients who have ingested any alcohol-containing mouthwash. Management strategies for ethanol-intoxicated patients are:

n  Supportive care is the mainstay of treatment.

n  Exclude other causes of altered mental status such as hypoglycemia, trauma, infection, co-ingestants, and stroke.

n  Evaluate and treat complications of ethanol intoxication such as hypothermia, hypoglycemia, and alcoholic ketoacidosis.

n  Nutritional support as needed: intravenous fluids with multivitamins, thiamine, and folic acid.

n  Monitor for ethanol withdrawal symptoms.

n  Monitor until clinically sober:

    The estimated rate of metabolism of ethanol ranges from 15 to 20 mg/dL per hour in the non-tolerant drinker, but may be as high as 25 to 35 mg/dL per hour in the tolerant drinker.


Suggested Reading

Lachenmeier DW, et al. What happens if people start drinking mouthwash as surrogate alcohol? A quantitative risk assessment. Food Chem Toxicol 2013;51:173.


Shulman JD, Wells LM. Acute ethanol toxicity from ingesting mouthwash in children younger than 6 years of age. Pediatr Dent 1997;19(6):404.


Soo Hoo GW, Hinds RL, et al. Fatal large-volume mouthwash ingestion in an adult: A review and the possible role of phenolic compound toxicity. J Intensive Care Med 2003;18(3):150.

Facebook Twitter

Tuesday, December 02, 2014

A 25-year-old man presents to the emergency department with palpitations. He reports injecting heroin, which he obtained from a new source, and is concerned that it was “not just heroin.” His initial vital signs include blood pressure 150/90 mm Hg, heart rate 130 bpm, respiratory rate 16 breaths per minute, and pulse oximetry 99% on room air. The patient appears uncomfortable, but is alert and oriented. His physical exam is remarkable for tachycardia and agitation.


The concern for an altered illicit drug is not uncommon in the ED. Cases and epidemics of tainted illicit drugs have been reported historically; the first reported heroin adulterant was quinine. A New York City outbreak of malaria in the 1930s was linked to IV drug abuse, and quinine, the mainstay of treatment at the time, was added to heroin to protect heroin


An epidemic of heroin adulterated with scopolamine occurred in the Northeast in the 1990s. Hamilton, et al. described patients who presented with respiratory depression after using heroin and then manifested signs of anticholinergic toxicity following naloxone administration. Another epidemic on the East Coast in 2005 involved heroin adulterated with clenbuterol. These patients presented with tachycardia, tremor, diaphoresis, hyperglycemia, hypokalemia, and lactic acidosis secondary to the beta-2 agonist effects of clenbuterol instead of manifesting a pure opiate toxidrome.


Xylazine, an alpha-2 agonist, was found as an adulterant in heroin in the early 2000s, and was thought to potentiate the high of heroin. It also resulted in more severe respiratory depression, hypotension, and bradycardia. More recently, emergency departments have had an increase in the number of heroin overdose patients resistant to the standard doses of naloxone. Adulterants like fentanyl and acetyl fentanyl are more potent than heroin, requiring a larger effective dose of naloxone and also causing numerous deaths in the United States.


Substances Often Used to Alter Illicit Drugs


      □ Unwanted substances, such as by-products of the manufacturing process


      □ Pharmacologically inert substance

      □ Bulking agents


      □ Pharmacologically active substance

      □ Enhance the drug effect or protect against a deleterious effect of the drug


      □ Replacement by another substance

      □ May have similar properties



Physicians should be aware of possible additives in illicit drugs used by patients with atypical presentations. Laboratory confirmation for additives is not readily available. Clinical presentation and regional trends may help guide identification and management.



Toxicologist Matthew Salzman, MD, of Cooper University Hospital assisted with this column.


Suggested Reading

Hoffman, RS, Kirrane BM, Marcus SM. A Descriptive Study of an Outbreak of Clenbuterol-Containing Heroin. Ann Emerg Med 2008;52(5):548.


Wong SC, Curtis JA, Wingert WE. Concurrent Detection of Heroin, Fentanyl, and Xylazine in Seven Drug-related Deaths Reported from the Philadelphia Medical Examiner’s Office. J Forensic Sci 2008;53(2):495.


Hamilton RJ, Perrone J, et al. A Descriptive Study of an Epidemic of Poisoning Caused by Heroin Adulterated with Scopolamine. Clin Toxicol 2000;38(6):597.

Facebook Twitter

About the Author

Gregory S. LaSala, MD; Rita G. McKeever, MD; and Jolene Okaneku, MD

Drs. LaSala, McKeever, and Okaneku are medical toxicology fellows at Drexel University College of Medicine in Philadelphia. Dr. LaSala, top, did his emergency medicine residency at Pennsylvania State University Hospital/Hershey Medical Center, and is a board member of the American College of Medical Toxicology Fellows in Training. Dr. McKeever, center, completed her residency at Drexel University College of Medicine and is a board member of the American College of Medical Toxicology Fellows in Training. Dr. Okaneku, bottom, is a graduate of Jefferson Medical College and of the emergency medicine residency at Drexel.

Blogs Archive